Oxford BioMedica plc (LON:OXB) insider Peter Nolan acquired 249,687 shares of Oxford BioMedica plc stock in a transaction dated Monday, July 17th. The stock was purchased at an average price of GBX 8 ($0.10) per share, with a total value of £19,974.96 ($26,022.62).
Oxford BioMedica plc (LON OXB) opened at 8.58 on Friday. The stock has a 50 day moving average price of GBX 7.58 and a 200 day moving average price of GBX 5.41. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 11.50. The stock’s market capitalization is GBX 264.61 million.
Several brokerages have recently issued reports on OXB. N+1 Singer raised their price objective on Oxford BioMedica plc from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) and gave the stock a “hold” rating in a research note on Thursday. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th. Finally, Jefferies Group LLC restated a “buy” rating and issued a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a research note on Thursday, July 13th.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.
